For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 83,608 | 59,836* | 83,843 | 80,913 |
| General and administrative | 35,799 | 28,571* | 28,853 | 23,658 |
| Total operating expenses | 119,407 | 88,406 | 112,696 | 104,571 |
| Loss from operations | -119,407 | -88,406* | -112,696 | -104,571 |
| Change in fair value of related party revenue share liability | -2,570 | -16,445* | -19,810 | -6,040 |
| Interest income and other income (expense), net | 12,866 | 12,779* | 10,201 | 11,103 |
| Total other income (expense), net | 10,296 | -3,666* | -9,609 | 5,063 |
| Loss before income taxes | -109,111 | -92,072* | -122,305 | -99,508 |
| Income tax provision | 168 | 170* | 132 | 145 |
| Net loss | -109,279 | -92,242* | -122,437 | -99,653 |
| Unrealized gains (losses) on marketable securities | -3,708 | 138* | 1,007 | 509 |
| Comprehensive loss | -112,987 | -92,104 | -121,430 | -99,144 |
| Basic EPS | -1.39 | -1.243 | -1.7 | -1.39 |
| Diluted EPS | -1.39 | -1.243 | -1.7 | -1.39 |
| Basic Average Shares | 78,670,371 | 74,073,007 | 72,143,466 | 71,843,774 |
| Diluted Average Shares | 78,670,371 | 74,073,007 | 72,143,466 | 71,843,774 |
Nuvalent, Inc. (NUVL)
Nuvalent, Inc. (NUVL)